ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sinphar Pharmaceutical Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$408 Mil.
Sinphar Pharmaceutical Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$6,140 Mil. Therefore, Sinphar Pharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2025 was 6.64%.
The historical rank and industry rank for Sinphar Pharmaceutical Co's ROA % or its related term are showing as below:
TPE:1734'
s ROA % Range Over the Past 10 Years
Min: -0.62 Med: 0.43 Max: 6.03
Current: 5.9
During the past 13 years, Sinphar Pharmaceutical Co's highest ROA % was 6.03%. The lowest was -0.62%. And the median was 0.43%.
TPE:1734's ROA % is ranked better than 89.01% of 1420
companies
in the Biotechnology industry
Industry Median: -32.87
vs TPE:1734: 5.90
Sinphar Pharmaceutical Co (TPE:1734) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sinphar Pharmaceutical Co (TPE:1734) has a ROA % of 6.64% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 1444% above median its historical median of 0.43. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #156 out of 1420 companies in the Biotechnology industry, placing it in the top 11%.
Is Sinphar Pharmaceutical Co's ROA % too high?
Sinphar Pharmaceutical Co's current ROA % of 6.64% is 1444% above median its 10-year median of 0.43. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #156 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #156 out of 1420 companies for ROA %. This places Sinphar Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current ROA % is 6.64%, which is 1444% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.00 — trading 3.4% below its estimated fair value. The current ROA % is 6.64%, which is 1444% above median its 10-year median of 0.43. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current ROA % is 6.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$32.00 is trading 3.4% below its estimated GF Value™ of NT$33.13.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
ROA %: 6.64% (1444% above median its 10-year median of 0.43)
GF Value™: NT$33.13 vs. price of NT$32.00 (3.4% below fair value)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
